Utilization of IV Antimicrobials Over a One-Year Period in Physician Office Infusion Centers

SAN DIEGO, CA (October 19, 2012) – A multi-center retrospective review of 11,616 patients receiving intravenous antimicrobials (IVAM) was conducted to determine utilization of IVAM in POICs and efficient device utilization. In the 65 participating POICs, patients received 15,256 multiple therapy regimens consisting of 15,499 drugs from January 1 to December 31, 2011. Of these therapies, 15,198 (98%) were antibiotics, 76 (<1%) were antivirals, and 225 (1%) were antifungals. The most prevalent diagnosis was skin and skin structure infections (27%) followed by osteomyelitis (16%). Patients were treated for over 50 diagnoses, and the primary device utilized to administer IVAM was an elastomeric device available for patients to take home. Secondarily, infusions were provided in the office by infusion or ambulatory pumps. A wide variety of IVAM, including high-risk agents, can be utilized in POICs for a broad range of diagnoses. The use of elastomeric devices was found to be the most significant factor in utilization, allowing for patient freedom and ease of use.

This study was presented at the 1st annual IDWeek™. For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected].

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

ABOUT IDWeek 2012
IDWeek 2012 is the first joint annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). With the theme—Advancing Science, Improving Care—IDWeek will feature the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2012 takes place October 17-21 at the San Diego Convention Center in San Diego, California.

For more information, visit www.idweek.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.